Correction to: Invest New Drugs (2020) 38(1):160–171
Corrections are needed to the original version of this article. The in-text citations of tables and figures in the section “results” are not in sequential order. Moreover in section “results” (Associations between treatment outcome and SNPs), the reader should read “Almost half the patients (43.5%, N = 41) were in the low-risk group” and not “Almost half the patients (43.5%, N = 53) were in the low-risk group”.
The authors apologize for corrections and further state that changes to the text and the sequence of figures and tables does not affect the overall outcome of the study.
Table 3 should show the univariate analysis for the 163 SNPs according to treatment outcome. Instead in the original paper it is presented in Table 4. For rs13900 the alleles associated with recessive model are “C/C or C/T” and not “C/C or T/T” as written in the table.
Table 5 should respectively show the weight of each SNP for multivariate predictive model according to treatment outcome and toxicity. Moreover in “Treatment outcome” the modality for rs13900 is T/T and not C/T.
Table 6 should show the classification of patients based on risk group and risk evaluation of each group. For a better reading of table, the results “Treatment Outcome” and “Toxicity” have been reversed.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s10637-019-00845-w
About this article
Cite this article
Refae, S., Gal, J., Ebran, N. et al. Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New Drugs 39, 287–292 (2021). https://doi.org/10.1007/s10637-020-00954-x